This file photo provided by Samsung Biologics shows its No. 4 plant in Songdo, just west of Seoul. (Image courtesy of Yonhap)
SEOUL, Jan. 14 (Korea Bizwire) — Samsung Biologics Co., a biotech arm of South Korea’s Samsung Group, said Tuesday it has received a contract manufacturing deal worth 2.07 trillion won (US$1.4 billion) from a Europe-based biopharmaceutical firm.
In the largest-ever contract manufacturing deal, Samsung Biologics will manufacture a biomedicine for the European company from Dec. 13, 2024, through Dec. 31, 2030, the company said in a regulatory filing.
The company didn’t provide the name of the medicine or the contractor.
The latest deal represents 40 percent of Samsung Biologics’ overall contracts won last year, worth 5.4 trillion won.
(Yonhap)
